We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
- Authors
Molina, Ana; Ginsberg, Michelle; Motzer, Robert; Molina, Ana M; Ginsberg, Michelle S; Motzer, Robert J
- Abstract
A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease progression after 3 months) and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib).
- Subjects
RENAL cell carcinoma; RENAL cancer; METASTASIS; PATHOLOGY; CANCER
- Publication
Medical Oncology, 2011, Vol 28, Issue 4, p1527
- ISSN
1357-0560
- Publication type
journal article
- DOI
10.1007/s12032-010-9640-y